Jan J Jobsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1275089/publications.pdf

Version: 2024-02-01

430442 552369 3,845 29 18 26 h-index citations g-index papers 29 29 29 3909 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet, The, 2000, 355, 1404-1411.	6.3	1,654
2	Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancerâ€"Combined Analysis of the PORTEC Cohorts. Clinical Cancer Research, 2016, 22, 4215-4224.	3.2	535
3	Fifteen-Year Radiotherapy Outcomes of the Randomized PORTEC-1 Trial for Endometrial Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, e631-e638.	0.4	282
4	Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials. European Journal of Cancer, 2015, 51, 1742-1750.	1.3	273
5	Postoperative radiotherapy for Stage 1 endometrial carcinoma: Long-term outcome of the randomized PORTEC trial with central pathology review. International Journal of Radiation Oncology Biology Physics, 2005, 63, 834-838.	0.4	233
6	Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer. Journal of the National Cancer Institute, 2015, 107, 402.	3.0	229
7	Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers. Journal of Clinical Oncology, 2016, 34, 409-418.	0.8	84
8	No Increased Risk of Second Cancer After Radiotherapy in Patients Treated for Rectal or Endometrial Cancer in the Randomized TME, PORTEC-1, and PORTEC-2 Trials. Journal of Clinical Oncology, 2015, 33, 1640-1646.	0.8	83
9	The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. International Journal of Radiation Oncology Biology Physics, 2003, 57, 724-731.	0.4	81
10	Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials. International Journal of Radiation Oncology Biology Physics, 2015, 91, 530-539.	0.4	59
11	Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer. Cancer Immunology Research, 2020, 8, 1508-1519.	1.6	45
12	Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. Annals of Surgery, 2019, 270, 364-372.	2.1	41
13	Differences in outcome for positive margins in a large cohort of breast cancer patients treated with breast-conserving therapy. Acta Oncológica, 2007, 46, 172-180.	0.8	39
14	The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival. British Journal of Cancer, 2017, 117, 179-188.	2.9	38
15	Timed Get Up and Go Test and Geriatric 8 Scores and the Association With (Chemo-)Radiation Therapy Noncompliance and Acute Toxicity inÂElderly Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 843-849.	0.4	31
16	Pattern of Ipsilateral Breast Tumor Recurrence After Breast-Conserving Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1006-1014.	0.4	29
17	The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor. Gynecologic Oncology, 2010, 117, 32-36.	0.6	23
18	Timing of radiotherapy and survival benefit in breast cancer. Breast Cancer Research and Treatment, 2006, 99, 289-294.	1.1	21

#	Article	IF	CITATIONS
19	Effect of External Boost Volume in Breast-Conserving Therapy on Local Control With Long-Term Follow-Up. International Journal of Radiation Oncology Biology Physics, 2008, 71, 115-122.	0.4	11
20	Outcome of Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement Only. Obstetrics and Gynecology International, 2011, 2011, 1-7.	0.5	10
21	Sequence of Radiotherapy and Chemotherapy in Breast Cancer After Breast-Conserving Surgery. International Journal of Radiation Oncology Biology Physics, 2012, 82, e811-e817.	0.4	9
22	Breast-conserving therapy for primary Ductal Carcinoma in Situ in The Netherlands: A multi-center study and population-based analysis. Breast, 2018, 42, 3-9.	0.9	9
23	Automated causal inference in application to randomized controlled clinical trials. Nature Machine Intelligence, 2022, 4, 436-444.	8.3	8
24	An actualised populationâ€based study on the use of radiotherapy in breast cancer patients in the Netherlands. Breast Journal, 2019, 25, 942-947.	0.4	7
25	Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer. Acta Oncológica, 2016, 55, 449-454.	0.8	6
26	The prognostic relevance of the mitotic activity index in axillary lymph node-negative breast cancer. Breast Cancer Research and Treatment, 2015, 149, 343-351.	1.1	5
27	Breast-conserving therapy in older patients with breast cancer over three decades: progress or stagnation. Journal of Geriatric Oncology, 2019, 10, 330-336.	0.5	О
28	The Mitotic Activity Index in combination with Her2neu: a strong prognosticator in breast cancer. Breast Cancer Research and Treatment, 2020, 181, 13-21.	1.1	0
29	Clinical relevance of the timing of radiotherapy after breast-conserving surgery. Strahlentherapie Und Onkologie, 2022, 198, 268-281.	1.0	0